本文選題：康婦炎膠囊　切入點(diǎn)：抗生素　出處：《中華中醫(yī)藥學(xué)刊》2017年02期

【摘要】：觀察康婦炎膠囊聯(lián)合抗生素治療對(duì)慢性盆腔炎患者臨床療效及炎癥因子水平影響,指導(dǎo)臨床治療與用藥。方法:醫(yī)院2015年1月—2016年3月婦科門(mén)診及病房收治的慢性盆腔炎患者74例隨機(jī)分為觀察組和對(duì)照組,每組37例,對(duì)照組采用抗生素治療,觀察組采用康婦炎膠囊+抗生素治療,兩組患者均治療14 d。治療后觀察兩組患者臨床療效,記錄治療前后血清中IL~(-1)(白介素-1)、IL-2(白介素-2)濃度表達(dá)情況及不良反應(yīng)發(fā)生情況。結(jié)果:治療后,觀察組患者總緩解率94.59%,對(duì)照組的總緩解率為86.49%,觀察組總緩解率顯著高于對(duì)照組,差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。與治療前比較,兩組患者IL~(-1)表達(dá)水平均降低,IL-2表達(dá)均升高,差異具有統(tǒng)計(jì)學(xué)意義(均P0.05);治療后組間比較,觀察組患者IL~(-1)及IL-2改善幅度由于對(duì)照組,差異具有統(tǒng)計(jì)學(xué)意義(均P0.05)。觀察組患者食欲不振、惡心、嗜睡及頭暈發(fā)病率與對(duì)照組水平相當(dāng),差異不具有統(tǒng)計(jì)學(xué)意義(均P0.05)。治療前后兩組患者血常規(guī)、生化指標(biāo)變化差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:對(duì)慢性盆腔炎患者在抗生素治療基礎(chǔ)上加用康婦炎膠囊能夠提高臨床療效,調(diào)整致炎和抗炎的動(dòng)態(tài)平衡,且安全可靠,值得臨床推廣使用。
[Abstract]:To observe the effect of Kangfuyan capsule combined with antibiotics on the clinical effect and inflammatory factor level of patients with chronic pelvic inflammatory disease.Methods: from January 2015 to March 2016, 74 patients with chronic pelvic inflammatory disease were randomly divided into observation group (n = 37) and control group (n = 37).The observation group was treated with Kangfuyan capsule antibiotics and the two groups were treated for 14 days.After treatment, the clinical efficacy of the two groups was observed, and the expression of IL-2in serum before and after treatment and the occurrence of adverse reactions were recorded.Results: after treatment, the total remission rate of the observation group was 94.59 and the total remission rate of the control group was 86.49. The total remission rate of the observation group was significantly higher than that of the control group, and the difference was statistically significant (P 0.05).Compared with before treatment, the expression level of IL1 in the two groups was significantly lower than that before treatment (all P 0.05) and the improvement of IL-2 in the observation group was statistically significant because of the control group (all P 0.05).The incidence of anorexia, nausea, lethargy and dizziness in the observation group was similar to that in the control group (all P 0.05).There was no significant difference in blood routine and biochemical indexes between the two groups before and after treatment (P 0.05).Conclusion: the application of Kangfuyan capsule on the basis of antibiotic therapy in patients with chronic pelvic inflammatory disease can improve the clinical efficacy, adjust the dynamic balance between inflammation and anti-inflammation, and be safe and reliable.
【作者單位】： 杭州市富陽(yáng)區(qū)婦幼保健院婦產(chǎn)科;
【分類(lèi)號(hào)】：R711.33

【相似文獻(xiàn)】

相關(guān)碩士學(xué)位論文 前1條

1 王璐;康婦炎膠囊治療濕熱瘀結(jié)型盆腔炎性疾病的臨床研究[D];浙江大學(xué);2016年

，

本文編號(hào)：1725498